Microdosing Protocol
Involves taking sub-perceptual doses of psychedelic substances (like psilocybin or LSD) to improve mood, creativity, and focus without producing psychoactive effects.
Overview
Microdosing involves taking approximately 1/20th to 1/10th of a recreational dose of a psychedelic substance, typically 0.1-0.3 grams of dried psilocybin mushrooms or 5-15 micrograms of LSD. Controlled laboratory studies show it affects blood pressure, sleep patterns, brain connectivity, social interactions, mood, and how you perceive pain and time. It works by stimulating serotonin receptors in the brain, particularly the 5-HT2A receptor, which helps reduce inflammation and promotes neuroplasticity by encouraging new brain connections to form. Recent placebo-controlled studies across 19 different labs found that microdosing creates real, measurable changes in brain function, mood, and thinking compared to taking a placebo.
Key Benefits
Microdosing may improve mood and mental performance by boosting increased BDNF levels, a protein that helps grow and maintain brain cells. People report enhanced creativity, better focus, and reduced depression and anxiety symptoms, though results vary significantly between individuals. Systematic observational research shows consistent improvements in mood, focus, and creativity when following structured dosing schedules. Use only pharmaceutical-grade substances at precisely calculated sub-perceptual doses with proper cycling protocols to maximise potential benefits whilst minimising legal and health risks.